- Home
- PFSI vs DMAC Comparison
PFSI vs DMAC Comparison
Compare PFSI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFSI
- DMAC
- Stock Information
- Founded
- PFSI 2008
- DMAC 2000
- Country
- PFSI United States
- DMAC United States
- Employees
- PFSI N/A
- DMAC N/A
- Industry
- PFSI Finance: Consumer Services
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- PFSI Finance
- DMAC Health Care
- Exchange
- PFSI Nasdaq
- DMAC Nasdaq
- Market Cap
- PFSI 5.0B
- DMAC 178.0M
- IPO Year
- PFSI 2013
- DMAC N/A
- Fundamental
- Price
- PFSI $99.15
- DMAC $3.89
- Analyst Decision
- PFSI Buy
- DMAC Strong Buy
- Analyst Count
- PFSI 6
- DMAC 2
- Target Price
- PFSI $121.17
- DMAC $8.00
- AVG Volume (30 Days)
- PFSI 326.8K
- DMAC 288.3K
- Earning Date
- PFSI 07-22-2025
- DMAC 08-06-2025
- Dividend Yield
- PFSI 1.20%
- DMAC N/A
- EPS Growth
- PFSI 123.72
- DMAC N/A
- EPS
- PFSI 6.51
- DMAC N/A
- Revenue
- PFSI $3,386,736,000.00
- DMAC N/A
- Revenue This Year
- PFSI N/A
- DMAC N/A
- Revenue Next Year
- PFSI $16.82
- DMAC N/A
- P/E Ratio
- PFSI $15.32
- DMAC N/A
- Revenue Growth
- PFSI 66.25
- DMAC N/A
- 52 Week Low
- PFSI $85.74
- DMAC $2.65
- 52 Week High
- PFSI $119.13
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- PFSI 56.43
- DMAC 46.89
- Support Level
- PFSI $93.94
- DMAC $3.58
- Resistance Level
- PFSI $99.07
- DMAC $3.96
- Average True Range (ATR)
- PFSI 2.02
- DMAC 0.29
- MACD
- PFSI 0.48
- DMAC -0.00
- Stochastic Oscillator
- PFSI 85.11
- DMAC 36.59
About PFSI PennyMac Financial Services Inc.
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform and integrated business focused on the production and servicing of U.S. residential mortgage loans. The company operates through two segments: production and servicing. The production segment performs loan origination, acquisition and sale activities. The servicing segment performs loan servicing for newly originated loans.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.